Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30540027 | 1.00 | FFAR4 (0.46) | FFAR4PDIA6IDH1EPHX2GPR3 | |
| SCHEMBL15212079 | 0.87 | FFAR4 (0.46) | FFAR4IDH1EPHX2GPR3KIF11 | |
| SCHEMBL6196375 | 0.83 | PDIA6 (0.59) | FFAR4PDIA6IDH1EPHX2GPR3 | |
| SCHEMBL29458350 | 0.83 | PDIA6 (0.59) | FFAR4PDIA6IDH1EPHX2GPR3 | |
| SCHEMBL30567116 | 0.81 | GPR3 (0.41) | FFAR4EPHX2GPR3KIF11CES1 | |
| SCHEMBL2437670 | 0.81 | GPR3 (0.41) | FFAR4EPHX2GPR3KIF11CES1 | |
| SCHEMBL1198803 | 0.81 | TRPV4 (0.49) | FFAR4GPR3KIF11CES1CHRM5 | |
| SCHEMBL29839101 | 0.81 | PDIA6 (0.45) | FFAR4PDIA6IDH1EPHX2GPR3 | |
| SCHEMBL2502219 | 0.81 | TRPV4 (0.57) | KIF11CES1CHRM5 | |
| SCHEMBL3691567 | 0.80 | WDR5 (0.43) | FFAR4GPR3KIF11CES1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154499-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-7718650-B2 | Aryl sulfonamide compounds for treating obesity | BIOVITRUM AB (SE) | 2010-05-18 | — | — | US | disclosed |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2010-05-06 | — | — | US | disclosed |
| US-7618961-B2 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-7566715-B2 | Substituted sulfonamide compounds useful for the prophylaxis and treatment of conditions relating to obesity, type II diabetes and/or disorders of the central nervous system | BIOVITRUM AB (SE) | 2009-07-28 | — | — | US | disclosed |
| US-20080096873-A1 | NEW COMPOUNDS | BIOVITRUM AB, A SWEDEN CORPORATION | 2008-04-24 | — | — | US | disclosed |
| US-7319097-B2 | Treatment of type II diabetes with benzenesulfonamide substituted with an N-heterocycle: N-[2-amino-5-(1,4-diazepan-1-yl)phenyl]benzenesulfonamide, N-[4-amino-5-(piperazinyl)phenyl]benzenesulfonamide, 3-amino-4-(5-methyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-N-phenyl-benzenesulfonamide hydrochloride | BIOVITRUM AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-7173035-B2 | Arylsulfonamide compounds | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060009446-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-01-12 | — | — | US | disclosed |
| US-20050288275-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2005-12-29 | — | — | US | disclosed |
| US-6969710-B2 | Compounds | BIOVITRUM AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2004-11-11 | — | — | US | disclosed |
| EP-1406884-A1 | ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030149020-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030149019-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-07 | — | — | US | disclosed |
| EP-1283831-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2003-02-19 | — | — | EP | disclosed |
| WO-2002092585-A1 | NOVEL, ARYLSUSFONAMIDE COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS-DISORDERS | BIOVITRUM AB (SE) | 2002-11-21 | — | — | WO | disclosed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149020-A1 | New compounds | GPR119, SULT2A1, NAT1 | FFAR4 192/4885PDIA6 1862/4885IDH1 2261/4885 |
| US-20040224996-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | FFAR4 3338/4885PDIA6 2551/4885IDH1 246/4885 |
| US-20030149019-A1 | New compounds | GPR119, SULT2A1, NAT1 | FFAR4 192/4885PDIA6 1862/4885IDH1 2261/4885 |
| US-20060009446-A1 | New compounds | GPR119, SULT2A1, STS | FFAR4 201/4885PDIA6 1774/4885IDH1 2261/4885 |
| US-20100113435-A1 | INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD3B1 | FFAR4 3228/4885PDIA6 2553/4885IDH1 382/4885 |
| US-20080096873-A1 | NEW COMPOUNDS | GPR119, SULT2A1, STS | FFAR4 201/4885PDIA6 1774/4885IDH1 2261/4885 |
| US-20050288275-A1 | New compounds | GPR119, SULT2A1, STS | FFAR4 201/4885PDIA6 1774/4885IDH1 2261/4885 |
| US-20250152574-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | FFAR4 3999/4885PDIA6 1500/4885IDH1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.